Transgene
ISIN
FR0005175080
Ticker
TNG
Sector
Sub-Industry
Country
France
Year Founded
1979
ISIN
FR0005175080
Ticker
TNG
Sector
Sub-Industry
Country
France
Year Founded
1979
Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
A pioneer in viral vectors engineering, we have one ambition: design innovative treatments in the fight against cancer.
Our approach uses the mechanisms of the immune response to enable the patient’s body to fight against disease.
160
Worldwide
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 85,453,000.00 | 101,838,000.00 | 66,436,000.00 |
| Noncurrent Assets | N/A | 54,766,000.00 | 39,593,000.00 | 19,930,000.00 |
| Property Plant And Equipment | N/A | 13,110,000.00 | 11,295,000.00 | 11,177,000.00 |
| Intangible Assets Other Than Goodwill | N/A | N/A | 92,000.00 | 77,000.00 |
| Other Noncurrent Nonfinancial Assets | N/A | N/A | 7,434,000.00 | 7,003,000.00 |
| Other Noncurrent Assets | N/A | 7,473,000.00 | 7,434,000.00 | N/A |
| Current Assets | N/A | 30,687,000.00 | 62,245,000.00 | 46,506,000.00 |
| Current Trade Receivables | N/A | N/A | 10,133,000.00 | 2,789,000.00 |
| Other Current Financial Assets | N/A | 21,077,000.00 | 43,658,000.00 | 22,423,000.00 |
| Other Current Nonfinancial Assets | N/A | N/A | 2,543,000.00 | 2,546,000.00 |
| Cash and cash equivalents | 1,343,000.00 | 5,277,000.00 | 5,911,000.00 | 4,403,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | N/A | N/A | 0.00 | 14,345,000.00 |
| Other Current Assets | N/A | 2,666,000.00 | 2,543,000.00 | N/A |
| Equity And Liabilities | N/A | 85,453,000.00 | 101,838,000.00 | 66,436,000.00 |
| Equity | N/A | 50,716,000.00 | 67,209,000.00 | N/A |
| Issued Capital | N/A | 41,921,000.00 | 48,886,000.00 | 50,102,000.00 |
| Retained Earnings Profit Loss For Reporting Period | N/A | N/A | -19,536,000.00 | -32,804,000.00 |
| Retained Earnings Excluding Profit Loss For Reporting Period | N/A | N/A | -31,092,000.00 | -50,628,000.00 |
| Equity Attributable To Owners Of Parent | N/A | N/A | 67,209,000.00 | 37,841,000.00 |
| Liabilities | N/A | 34,737,000.00 | 34,629,000.00 | 28,595,000.00 |
| Noncurrent Liabilities | N/A | 21,108,000.00 | 20,040,000.00 | 15,813,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | N/A | 3,958,000.00 | 3,282,000.00 |
| Other Noncurrent Nonfinancial Liabilities | N/A | N/A | 841,000.00 | 204,000.00 |
| Other Noncurrent Liabilities | N/A | 110,000.00 | 841,000.00 | N/A |
| Longterm Borrowings | N/A | N/A | 15,241,000.00 | 12,327,000.00 |
| Current Liabilities | N/A | 13,629,000.00 | 14,589,000.00 | 12,782,000.00 |
| Current Provisions | N/A | 511,000.00 | 48,000.00 | 23,000.00 |
| Trade And Other Current Payables | N/A | N/A | 7,692,000.00 | 6,965,000.00 |
| Other Current Nonfinancial Liabilities | N/A | N/A | 5,454,000.00 | 4,602,000.00 |
| Other Current Liabilities | N/A | 6,626,000.00 | 5,454,000.00 | N/A |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | N/A | 1,395,000.00 | 1,192,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 2,981,000.00 | 9,993,000.00 | N/A |
| Revenue From Contracts With Customers | N/A | 9,993,000.00 | 3,126,000.00 |
| Other Income | 572,000.00 | 399,000.00 | 342,000.00 |
| Profit Loss From Operating Activities | -23,993,000.00 | -23,525,000.00 | -29,904,000.00 |
| Profit Loss Before Tax | -17,231,000.00 | -19,536,000.00 | -32,804,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -17,231,000.00 | -19,536,000.00 | -32,804,000.00 |
| Profit Loss Attributable To Owners Of Parent | -17,224,000.00 | -19,908,000.00 | N/A |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -17,231,000.00 | -19,536,000.00 | -32,804,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | 717,000.00 | -242,000.00 | N/A |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | -2,057,000.00 | 2,657,000.00 | -750,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | N/A | 2,521,000.00 | 1,686,000.00 |
| Adjustments For Provisions | N/A | 722,000.00 | -1,031,000.00 | 191,000.00 |
| Adjustments For Sharebased Payments | N/A | 1,744,000.00 | 3,002,000.00 | 2,675,000.00 |
| Other Adjustments For Noncash Items | N/A | -320,000.00 | -112,000.00 | -41,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -28,742,000.00 | -25,909,000.00 | -20,303,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 17,742,000.00 | -5,789,000.00 | 20,272,000.00 |
| Proceeds From Issuing Shares | N/A | 0.00 | 34,129,000.00 | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 1,514,000.00 | 1,277,000.00 | 1,281,000.00 |
| Proceeds From Government Grants Classified As Financing Activities | N/A | 655,000.00 | 603,000.00 | 455,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | 21,041,000.00 | -22,582,000.00 | N/A |
| Cash Flows From Used In Financing Activities | N/A | 14,941,000.00 | 32,320,000.00 | -1,477,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -7,000.00 | 12,000.00 | 0.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 3,934,000.00 | 634,000.00 | -1,508,000.00 |
| Cash and cash equivalents | 1,343,000.00 | 5,277,000.00 | 5,911,000.00 | 4,403,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 26.05.2023 | None | Other | Buy | EUR 0.00 |
FR0005175080
969500PDJW8N0FSGGK69
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.